Dr. David Fajgenbaum, one of the founders of Every Cure, a nonprofit focused on drug repurposing. Courtesy of Every Cure A version of this story first appeared in the CNBC Cures newsletter. Click here to sign up. There are over 10,000 rare diseases — 95% of which don’t have a cure. It can cost billions…
Abivax is planning to raise money after releasing key trial data in June, its CEO told CNBC on Tuesday, signaling to potential buyers of the firm that it is in no rush to sell. Intense takeover rumors have surrounded the French biotech company for months, impacting the volatile stock that rose nearly 1,700% in 2025….
Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration. The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from…
The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the…
Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe’s most valuable company. But its troubles are stacking up and today the stock trades at just a quarter of what it did at its peak less than two years ago. Pricing pressure, fierce competition, and pipeline setbacks have…
